XTNT

SEC Filing Summary: Bacterin International Holdings, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Bacterin International Holdings, Inc. for the period ended March 31, 2011. The company develops, manufactures, and markets biologics products (human allografts for bone and tissue growth) and medical device coatings. The company completed a reverse merger in June 2010 and is currently transitioning from a distributor-based model to a direct sales force model. Approximately 98% of sales are derived from the United States.

Key Financial Metrics

Note: Net Income for Q1 2011 is driven primarily by a non-cash gain of $7,218,806 related to the change in fair value of warrant derivative liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 119% year-over-year, driven by market penetration and the expansion of the direct sales force.
• Operating Expenses: Total operating expenses increased 120% to $6.95 million. Sales and marketing expenses surged 196% to $4.26 million due to increased commissions, travel, and marketing activities associated with the new sales model.
• Profitability: While the company reported a Net Loss of $1.64 million in Q1 2010, it reported Net Income of $4.92 million in Q1 2011. This reversal is almost entirely attributable to the non-cash accounting gain on warrant derivatives, as the company still incurred an operating loss of $1.94 million.
• Liquidity: Cash flow from operations was negative ($1.59 million used), primarily due to increases in accounts receivable and inventory. Financing activities provided $1.86 million, largely from a drawdown on a new revolving credit facility.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur approximately $20 million in sales and marketing expenses in 2011 (up from $9 million in 2010) to fund growth. They believe current cash, receivables, and credit facilities are sufficient to meet requirements through June 30, 2012.
• Capital Needs: The company anticipates needing $4–$5 million over the next five years to expand facilities. Failure to meet revenue objectives may require additional equity financing (dilution) or debt.
• Internal Controls: Management concluded that internal controls over financial reporting were ineffective as of March 31, 2011, citing material weaknesses including insufficient accounting personnel, a lack of integration between inventory and accounting systems, and inadequate documentation for equity transactions.
• Risks: Key risks include reliance on donor cadavers, competitive market pressures, government reimbursement changes, and ongoing litigation (including patent infringement claims and non-compete disputes).
• Subsequent Events: On May 3, 2011, the company raised $1.87 million in a private placement. A preliminary letter of intent was signed to acquire Robinson MedSurg LLC for $1 million in stock plus potential earn-outs.

Investor Verification Checklist

• Quality of Earnings: Verify the sustainability of the Q1 2011 net income, noting it is driven by a non-cash derivative gain rather than core operations.
• Working Capital: Monitor the rapid growth in Accounts Receivable ($4.2M) and Inventory ($7.3M total) relative to cash burn and collection cycles.
• Debt Covenants: Review the terms of the $5 million Bridge Bank credit facility and the WTI debt facility, specifically regarding profitability milestones required to access additional funds.
• Internal Control Remediation: Track progress on hiring accounting staff and integrating inventory/accounting systems to address the material weaknesses disclosed.
• Litigation Status: Monitor the outcomes of the minSURG patent infringement case and the Musculoskeletal Transplant Foundation non-compete settlement.